Targeted Oncology Staff

During a live event, the benefit of adding nivolumab (Opdivo) to tivozanib (Fotivda) in the second-line setting was discussed by David Braun, MD, and participants.

Genomic assays guide adjuvant therapy in HR-positive, HER2-negative breast cancer, clarifying who benefits from chemo by age, nodal status, and risk score.

Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy.

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future role.

During a live event, Shaji Kumar, MD, discussed dose deescalation as a strategy for managing adverse events with talquetamab in multiple myeloma.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Oncology shifts fast: tazemetostat pulled, giredestrant PFS miss, and new ADC and NSCLC guideline strategies refine metastatic care.

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment.

During a live event, Daniel Olson, MD, reviewed a patient case of recurrent melanoma with brain metastases and addressed treatment options.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Overcoming ESA-refractory MDS involves greater use of targeted agents based on the patient's molecular profile.

FDA’s February oncology surge brings new pancreatic TTFields, PD-1 win in ovarian cancer, AI tools, and key trial setbacks.

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma.

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

Using the best medication available in the frontline setting of RCC leads to optimal results.

Experts explain how MRI trends, seizures, and spectroscopy guide when IDH-mutant glioma monitoring ends and radiation or chemo begins.

FDA oncology updates in February 2026 deliver new approvals, oral and monthly dosing options, and key NDA reviews, easing treatment burden across hard-to-treat cancers.

ASCO GU 2026 previews and FDA rulings spotlight new targeted options in bladder, lung, breast, and colorectal cancers.

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines.

During a live event, Joshua Richter, MD, discussed dosing strategies when using selinexor in relapsed/refractory multiple myeloma.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

BCMA bispecific teclistamab delivers 63% responses and durable remissions in heavily pretreated myeloma, with new infection prophylaxis insights.

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Explore this week’s oncology breakthroughs: genomic-driven lung cancer care, record survival gains, and FDA moves in myeloma and subcutaneous amivantamab.

During a Case-Based Roundtable event, Timothy Cloughesy, MD, and participants discuss targeted IDH inhibition in patients with grade 2 gliomas.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed how recent trial findings are affecting their treatment of newly diagnosed multiple myeloma.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.